BNR Fundamental Analysis - BURNING ROCK BIOTECH LTD-ADR

Fundamental Rating

BNR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. BNR has a bad profitability rating. Also its financial health evaluation is rather negative. BNR is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BNR has reported negative net income.

In the past year BNR has reported a negative cash flow from operations.

In the past 5 years BNR always reported negative net income.

BNR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BNR's Return On Assets of -14.93% is fine compared to the rest of the industry. BNR outperforms 80.00% of its industry peers.

Looking at the Return On Equity, with a value of -22.06%, BNR belongs to the top of the industry, outperforming 81.70% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-14.93%
ROE	-22.06%
ROIC	N/A

ROA(3y)-54.4%

ROA(5y)-43.17%

ROE(3y)-76.2%

ROE(5y)-58.25%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 73.02%, BNR belongs to the top of the industry, outperforming 82.83% of the companies in the same industry.

In the last couple of years the Gross Margin of BNR has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for BNR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	73.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.68%

GM growth 5Y-0.38%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BNR does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, BNR has about the same amount of shares outstanding.

The number of shares outstanding for BNR has been increased compared to 5 years ago.

BNR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

BNR has an Altman-Z score of -2.88. This is a bad value and indicates that BNR is not financially healthy and even has some risk of bankruptcy.

BNR has a Altman-Z score of -2.88. This is comparable to the rest of the industry: BNR outperforms 46.79% of its industry peers.

BNR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

BNR's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. BNR outperforms 47.55% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.88

ROIC/WACCN/A

WACC7.54%

2.3 Liquidity

BNR has a Current Ratio of 3.14. This indicates that BNR is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of BNR (3.14) is worse than 62.83% of its industry peers.

A Quick Ratio of 2.91 indicates that BNR has no problem at all paying its short term obligations.

BNR's Quick ratio of 2.91 is on the low side compared to the rest of the industry. BNR is outperformed by 63.40% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.14
Quick Ratio	2.91

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 93.72% over the past year.

BNR shows a small growth in Revenue. In the last year, the Revenue has grown by 5.56%.

The Revenue has been growing slightly by 6.21% on average over the past years.

EPS 1Y (TTM)93.72%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%55.1%

Revenue 1Y (TTM)5.56%

Revenue growth 3Y0.52%

Revenue growth 5Y6.21%

Sales Q2Q%2.31%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

BNR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.51% yearly.

EPS Next Y-277.41%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year48.35%

Revenue Next 2Y17.89%

Revenue Next 3Y16.85%

Revenue Next 5Y15.51%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BNR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BNR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

BURNING ROCK BIOTECH LTD-ADR

NASDAQ:BNR (12/30/2025, 1:45:04 PM)

After market: 21.34 +0.51 (+2.45%)

20.83

+0.25 (+1.21%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)12-02 2025-12-02

Earnings (Next)03-23 2026-03-23/amc

Inst Owners21.19%

Inst Owner Change-17.12%

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap213.69M

Revenue(TTM)539.27M

Net Income(TTM)-121.25M

Analysts80

Price TargetN/A

Short Float %0.72%

Short Ratio0.85

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2.78
P/FCF	N/A
P/OCF	N/A
P/B	2.72
P/tB	2.73
EV/EBITDA	N/A

EPS(TTM)-1.74

EYN/A

EPS(NY)-1.02

Fwd EYN/A

FCF(TTM)-0.45

FCFYN/A

OCF(TTM)-0.45

OCFYN/A

SpS7.5

BVpS7.65

TBVpS7.64

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.93%
ROE	-22.06%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	73.02%
FCFM	N/A

ROA(3y)-54.4%

ROA(5y)-43.17%

ROE(3y)-76.2%

ROE(5y)-58.25%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.68%

GM growth 5Y-0.38%

F-Score5

Asset Turnover0.66

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.14
Quick Ratio	2.91
Altman-Z	-2.88

F-Score5

WACC7.54%

ROIC/WACCN/A

Cap/Depr(3y)26.43%

Cap/Depr(5y)152.99%

Cap/Sales(3y)5.44%

Cap/Sales(5y)15.37%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)93.72%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%55.1%

EPS Next Y-277.41%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)5.56%

Revenue growth 3Y0.52%

Revenue growth 5Y6.21%

Sales Q2Q%2.31%

Revenue Next Year48.35%

Revenue Next 2Y17.89%

Revenue Next 3Y16.85%

Revenue Next 5Y15.51%

EBIT growth 1Y79.72%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y89.46%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y89.46%

OCF growth 3YN/A

OCF growth 5YN/A

BURNING ROCK BIOTECH LTD-ADR / BNR FAQ

Can you provide the ChartMill fundamental rating for BURNING ROCK BIOTECH LTD-ADR?

ChartMill assigns a fundamental rating of 2 / 10 to BNR.

What is the valuation status of BURNING ROCK BIOTECH LTD-ADR (BNR) stock?

ChartMill assigns a valuation rating of 0 / 10 to BURNING ROCK BIOTECH LTD-ADR (BNR). This can be considered as Overvalued.

What is the profitability of BNR stock?

BURNING ROCK BIOTECH LTD-ADR (BNR) has a profitability rating of 2 / 10.

Can you provide the expected EPS growth for BNR stock?

The Earnings per Share (EPS) of BURNING ROCK BIOTECH LTD-ADR (BNR) is expected to decline by -277.41% in the next year.

BURNING ROCK BIOTECH LTD-ADR (BNR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BURNING ROCK BIOTECH LTD-ADR / BNR FAQ

Can you provide the ChartMill fundamental rating for BURNING ROCK BIOTECH LTD-ADR?

What is the valuation status of BURNING ROCK BIOTECH LTD-ADR (BNR) stock?

What is the profitability of BNR stock?

Can you provide the expected EPS growth for BNR stock?